Recent Articles By The Author
Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
The S&P 500 began the year selling at 18.2x forward earnings. It is now at around 15x projected earnings.
These stocks are deep in bargain territory.